CareDx (CDNA) has had the highest return since January 1, 2026 by a mid-cap US stock, returning 364%.
| ASSET | % RETURN |
|---|---|
CareDx (CDNA) | 363.96% |
Veradermics (MANE) | 310.85% |
Immunitybio (IBRX) | 310.4% |
Erasca (ERAS) | 286.79% |
MaxLinear (MXL) | 278.41% |
Pulse Biosciences (PLSE) | 277.73% |
Okeanis Eco Tankers (ECO) | 259.9% |
Abcellera Biologics (ABCL) | 258.77% |
Kodiak Sciences (KOD) | 255.36% |
AXT (AXTI) | 220.12% |
Oruka Therapeutics (ORKA) | 219.6% |
Absci (ABSI) | 213.52% |
Hyperliquid Strategies Inc Common Stock (PURR) | 211.9% |
Iovance Biotherapeutics (IOVA) | 205.04% |
Spyre Therapeutics (SYRE) | 194.75% |
PBF Energy (PBF) | 190.68% |
Enliven Therapeutics (ELVN) | 185.48% |
Ringcentral (RNG) | 182.36% |
Definium Therapeutics (DFTX) | 169.11% |
International Seaways (INSW) | 166.28% |
Penguin Solutions (PENG) | 161.22% |
Iridium Communications (IRDM) | 159.55% |
Lindblad Expeditions (LIND) | 158.3% |
Tango Therapeutics (TNGX) | 156.72% |
Delek US Energy (DK) | 152.12% |
Mid-cap stocks are treated as having a market cap between $2B and $10B.